RhoVac AB is a Sweden-based biotechnology company. The Company specializes on research and development of immunotherapeutic drugs. The Company's primarily focus is to develop a therapeutic cancer vaccine with the potential to prevent or limit metastasis and progression in cancer after primary tumor therapy. Its main drug candidate is RV001, an immuno-oncologic drug that is presented to the immune system as an antigen, stimulating T-cells to identify and destroy cells that carry protein called RhoC, that is metastatic or metastatic potential cells.